# A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

> **NCT04916002** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma
- Basal Cell Carcinoma
- Triple Negative Breast Cancer
- Non-Small Cell Lung Cancer
- Oropharynx Squamous Cell Carcinoma

## Interventions

- **DRUG:** vidutolimod
- **DRUG:** cemiplimab

## Key facts

- **NCT ID:** NCT04916002
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-30
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-10-31
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Sponsor Decision related to study drug supply
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916002, "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04916002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*